These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 33731992

  • 21. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A.
    Respir Res; 2014 Jul 11; 15(1):78. PubMed ID: 25015176
    [Abstract] [Full Text] [Related]

  • 22. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 11; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 23. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
    Hanania NA, Caveney S, Soule T, Tombs L, Lettis S, Crim C, Mannino DM, Patel H, Boucot IH.
    Int J Chron Obstruct Pulmon Dis; 2021 Jul 11; 16():1925-1938. PubMed ID: 34194225
    [Abstract] [Full Text] [Related]

  • 24. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M, Bengtson LGS, Johnson MG, Bunner SH, Gronroos NN, DiRocco KK.
    Int J Chron Obstruct Pulmon Dis; 2024 Jul 11; 19():97-110. PubMed ID: 38226396
    [Abstract] [Full Text] [Related]

  • 25. Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
    Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L.
    Ther Adv Respir Dis; 2020 Jul 11; 14():1753466620926949. PubMed ID: 32462979
    [No Abstract] [Full Text] [Related]

  • 26. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS.
    Int J Chron Obstruct Pulmon Dis; 2022 Jul 11; 17():491-504. PubMed ID: 35281476
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 11; 18():407-418. PubMed ID: 36998390
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 11; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec 11; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Dec 11; 18():2039-2054. PubMed ID: 37731774
    [Abstract] [Full Text] [Related]

  • 35. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul 11; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 36. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
    Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.
    Chest; 2014 May 11; 145(5):981-991. PubMed ID: 24385182
    [Abstract] [Full Text] [Related]

  • 37. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
    Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 May 11; 17():1455-1466. PubMed ID: 35769225
    [Abstract] [Full Text] [Related]

  • 38. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N.
    Clin Ther; 2014 Jul 01; 36(7):1016-1027.e2. PubMed ID: 24947493
    [Abstract] [Full Text] [Related]

  • 39. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul 01; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
    Zhou Y, Duan S, Zhang L, Peng F.
    Respir Med; 2024 May 01; 226():107632. PubMed ID: 38621548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.